Correction

Article Outline

• Copyright

In the article by Gurm et al (Effectiveness and safety of bivalirudin during percutaneous coronary intervention in a single medical center,” vol. 95, no. 6, March 15, 2005, pp. 716–721), there were several errors that appeared in Tables 1 and 3. In, Table 1, the patients receiving the bivalirudin based regimen should read 205 (19.2%) instead of 205 (18.2%). Also, in Table 1, the patients receiving the bivalirudin based regimen with platelet glycoprotein IIb/IIIa inhibitors should read 206 (19.3%) instead of 352 (19.3%). In Table 3, column 2, the patients receiving bivalirudin based regimen with restenotic lesions should read 205 (19.2%) instead of 205 (18.2%). Also, in column 2, the patients receiving the bivalirudin based regimen with platelet glycoprotein IIb/IIIa inhibitors should read 206 (19.3%) instead of 352 (19.3%). In Table 3, column 5, the patients receiving the bivalirudin based regimen with restenotic lesions should read 175 (20.3%) instead of 175 (24.6%).